These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30621390)

  • 1. Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy.
    Liu Y; Chen XG; Yang PP; Qiao ZY; Wang H
    Biomacromolecules; 2019 Feb; 20(2):882-892. PubMed ID: 30621390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
    Liu D; Li K; Gong L; Fu L; Yang D
    Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
    Merino M; Lozano T; Casares N; Lana H; Troconiz IF; Ten Hagen TLM; Kochan G; Berraondo P; Zalba S; Garrido MJ
    J Nanobiotechnology; 2021 Apr; 19(1):102. PubMed ID: 33849551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy.
    Su Z; Xiao Z; Huang J; Wang Y; An Y; Xiao H; Peng Y; Pang P; Han S; Zhu K; Shuai X
    ACS Appl Mater Interfaces; 2021 Mar; 13(11):12845-12856. PubMed ID: 33709684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
    Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
    ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
    Tu K; Yu Y; Wang Y; Yang T; Hu Q; Qin X; Tu J; Yang C; Kong L; Zhang Z
    ACS Appl Mater Interfaces; 2021 Aug; 13(33):39003-39017. PubMed ID: 34433253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MMP-responsive transformation nanomaterials with IAP antagonist to boost immune checkpoint therapy.
    Wang T; He Z; Yuan CS; Deng ZW; Li F; Chen XG; Liu Y
    J Control Release; 2022 Mar; 343():765-776. PubMed ID: 35181414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.
    Gu Z; Wang Q; Shi Y; Huang Y; Zhang J; Zhang X; Lin G
    J Control Release; 2018 Sep; 286():369-380. PubMed ID: 30096401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
    Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
    Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
    Du Y; Liang X; Li Y; Sun T; Xue H; Jin Z; Tian J
    Cancer Lett; 2018 Feb; 414():230-238. PubMed ID: 29175457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pH-sensitive charge-conversional and NIR responsive bubble-generating liposomal system for synergetic thermo-chemotherapy.
    Chen MM; Song FF; Feng M; Liu Y; Liu YY; Tian J; Lv F; Zhang QQ
    Colloids Surf B Biointerfaces; 2018 Jul; 167():104-114. PubMed ID: 29631221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
    Ou W; Jiang L; Gu Y; Soe ZC; Kim BK; Gautam M; Poudel K; Pham LM; Phung CD; Chang JH; Kim JR; Ku SK; Yong CS; Kim JO
    ACS Appl Mater Interfaces; 2019 Oct; 11(40):36333-36346. PubMed ID: 31535550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimuli-responsive polymer-doxorubicin conjugate: Antitumor mechanism and potential as nano-prodrug.
    Chen K; Cai H; Zhang H; Zhu H; Gu Z; Gong Q; Luo K
    Acta Biomater; 2019 Jan; 84():339-355. PubMed ID: 30503561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.
    Gao F; Zhang C; Qiu WX; Dong X; Zheng DW; Wu W; Zhang XZ
    Small; 2018 Sep; 14(37):e1802403. PubMed ID: 30129176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.